BIOGEN HIRULOG AND CD4 DRY HOLES EXHIBIT IMPORTANCE OF OUTSOURCING STRATEGY, EXEC SAYS: MORE COSTLY IN SHORT-TERM BUT PERMITS SUSTAINABLE MULTIPLE PROJECTS
Executive Summary
Biogen's decision to use a "virtual" drug development approach in the early 1990s has helped it to weather two significant dry holes and to maintain a degree of stability, Associate Director of Medical Operations Gunther Winkler, PhD, indicated in a presentation at an April 20-21 meeting on "Virtual Corporation Strategies" in Boston.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth